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INTRODUCTION
The population of the Middle East countries is increasing as a
result of increased birth rates and growth of the pediatric
population. Consequently, the number of children at risk of cancer
is increasing rapidly. With the control of infectious diseases and
malnutrition, cancer has now assumed a prominent position among
the primary causes of morbidity and mortality in children.
Childhood acute lymphoblastic leukemia (ALL), the most
common malignancy comprises around 25% of childhood
malignancies [1]. Little is known about its clinical and laboratory
profile in the Middle East apart from limited single institutional or
national studies [2–11]. Additionally, there are few data concerning
the types of protocols used in the Middle East, their remission
induction rates and induction toxicities.
The Middle East Childhood Cancer Alliance (MECCA) was
established in 2000 and is comprised of member institutions in 16
countries in the Middle East and surrounding area. This article
reports the results ofMECCA’s first prospective, multi-institutional,
and international prospective collaborative study that provides
Background. Little is known about childhood ALL in the Middle
East. This study was undertaken by MECCA as initial efforts in
collaborative data collection to provide clinical and demographic
information on children with ALL in the Middle East. Procedure.
Clinical and laboratory data for patients with ALL between January
2008 and April 2012 were prospectively collected from institutions
in 14Middle East countries and entered into a custom-built-database
during induction phase. All laboratory studies including cytogenet-
ics were done at local institutions. Results. The 1,171 voluntarily
enrolled patients had a mean age of 6.13.9 years and 59.2% were
boys. T-ALL represented 14.8% and 84.2% had B-precursor ALL. At
diagnosis, 5.6% had CNS disease. The distribution of common
genetic abnormalities reflected a similar percentage of hyper-
diploidy (25.6%), but a lower percentage of ETV6–RUNX1
translocation (14.7%) compared to large series reported from
Western populations. By clinical criteria, 47.1% were low/standard
risk, 16.9% were intermediate risk, and 36% were high risk. Most
patients received all their care at the same unit (96.9%). Patients had
excellent induction response to chemotherapy with an overall
complete remission rate of 96%. Induction toxicities were accept-
able. Conclusions. This first collaborative study has established a
process for prospective data collection and future multinational
collaborative research in the Middle East. Despite the limitations of
an incomplete population-based study, it provides the first
comprehensive baseline data on clinical characteristics, laboratory
evaluation, induction outcome, and toxicity. Further work is
planned to uncover possible biologic differences of ALL in the
region and to improve diagnosis and management. Pediatr Blood
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clinical characteristics, laboratory evaluation, induction therapy
outcomes, and toxicity of ALL in the Middle East. It was decided
that an initial focus of this group should be on the ability to collect
high quality clinical, laboratory, and demographic data by limiting
this study to the induction phase, given the variability in approaches
to subsequent treatment.
The data presented in this article represent the collective
experience of the majority of institutions in the Middle East and
several surrounding countries involved in the management of ALL
(Fig. 1). The aims of the study were to (1) assess feasibility and
establish mechanisms for collaborative data collection and
management in the Middle East and (2) to collect prospective
data on childhood ALL which would serve as background for
subsequent clinical studies.
MATERIALS AND METHODS
Study Design
This study was designed as a multicenter descriptive study to
collect and analyze prospective data from January 2008 to
April 2012 on a variety of parameters. Of the 16 member countries,
14 countries were able to participate (Fig. 1).
Eligibility Criteria
Eligibility criteria included (1) age at diagnosis younger than
18 years of age; (2) the patient being a resident of one of 14 member
countries; and (3) having the diagnosis of new onset ALL during the
years 2008–2012. Diagnoses had to be confirmed by immunophe-
notyping at the treating hospitals, except in Yemen, where the
diagnosis was based on morphology and histochemistry only.
Data Collection Tools and Methods
A web-based electronic form (SQL format) was designed to
collect data. Each country’s primary investigator was assigned a
country number and protected password. Because ALL treatment is
lengthy (2–3 years) and varies with different protocols, it was agreed
to limit data collection to the induction phase for this initial study.
The following data were collected using data capture form
(DCF) and included: demographic, clinical, laboratory, morpho-
logic, immunophenotypic, and cytogenetic characterization, mo-
lecular genetics using fluorescence in situ hybridization (FISH) and
polymerase chain reaction (PCR) methods, response to therapy
during and at the end of induction, toxicity profile during induction,
and types of protocols/treatment. All collected data were sent
electronically to MECCA coordinating office. Quality of data
(review of completeness, accuracy, security, and confidentiality of
data) was maintained by an assigned research coordinator. All
missing fields were verified as truly not available.
Mechanisms for Data Collection
Investigators and research assistants were identified for each
country. The procedures for data collection, entry, storage, and data
validation were established. A data dictionary and case report form
(CRF) were created and a database was developed using Microsoft
SQL server (2005) with a web-enabled front end. The database was
housed at King Faisal Specialist Hospital and Research Center-
MECCA Office, Saudi Arabia and at MECCA Office, Hamad
Medical Corporation, Qatar with MECCA as the responsible
authority. Remote, password-protected access was provided to each
of the countries. Data were extracted from electronic- and paper-
based medical records in each country and entered on the CRF.
Original CRF hard copies were maintained securely at each
treatment center. Data were entered from each participating center
under an institutional and patient unique MECCA identifying
number. Data verification, validation, and evaluation of accuracy
were performed at regular intervals at MECCA Office, Qatar.
Patients and Clinical Data
This study was approved by the authorized clinical research and
ethics committees of each center. Informed consents were collected
and filed for all patients. Five patient consents were misplaced and
those patients were excluded from the study.
Once all data had been entered into the central database, it was
audited by one of the Principal Investigators (AA) and the study
coordinator/study statistician (PC). Any missing or ambiguous
entries were first cross-checked with the CRF copies maintained at
MECCA offices and, if not resolved, were discussed at phone or
video conference with MECCA investigators for detailed clarifica-
tion and corrective measures.
Statistical Analyses
Categorical and continuous values were expressed as frequency,
percentage, mean, median, standard deviation (SD), and range.
Descriptive statistics were used to summarize all demographic,
clinical, laboratory, and other characteristics of the patients.
Response and outcome during and at the end of induction were
studied. Quantitative variables means between the two and more
than two independent groups were analyzed using unpaired t-test,
Mann–Whitney U-test, one-way analysis of variance (ANOVA),
and Kruskal–Wallis tests. Associations between two or more
qualitative variables were assessed using chi-squared test. For small
frequencies, chi-squared test with continuity correction factor or
Fisher exact test was applied. Pictorial presentations of the key
results were made using appropriate statistical graphs. A two-sided
P-value <0.05 was considered to be statistically significant. All
statistical analyses were done using statistical packages SPSS 19.0
(SPSS, Chicago, IL).
RESULTS
Patient Characteristics
The study was open to all MECCA countries and 14 countries
participated. As enrollment was voluntary, not all patients from an
individual center representing each of the participating countries
were enrolled on this study. Therefore, this was not a full population-
based study. The statistical analysis was based on a total of 1,171
enrolled patients. Due to population differences and variable
abilities to address the logistical challenges of collaborative clinical
research, there were significant differences in the number of patients
enrolled; about 75% were submitted by five countries with one
contributing 25% of the total number of patients (Fig. 1A).
There were 692 (59.2%) male and 479 (40.8%) females with
male to female ratio of 1.4:1 (Table I). The mean age at diagnosis
was 6.1 3.9 years (range; 0.2–18 years). The majority of patients
926 (79.4%) were within the 1–10 years of age, 214 (18.4%)
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patients were 10 years or older, and 26 (2.2%) were infants. Peak
incidence was observed at 3–6 years of age comprising (33.8%) as
shown in Figure 1B.
Of the 1,150 patients reported, 1,114 (96.9%) patients began and
continued treatment at the same hospital. Only 36 (3.1%) received
care at different hospitals (Table I). Pallor was the most frequent
symptom noted in 901 (79.2%) followed by fever in 870 (75.5%)
and bone pain in 434 (39.6%). Lymphadenopathy was noted in 712
(62.6%), splenomegaly in 696 (60.8%) and hepatomegaly in 681
(59.5%), testicular involvement was diagnosed clinically in 185
(26.7%) of the patients at diagnosis, but was only proven by biopsy
in 17 (2.4%). Other signs and symptoms are shown in Table I.
Themedian duration of symptoms before diagnosis was 1month
and ranged from 0.1 to 15 months. The majority of patients 900
(87.4%) presented with normal weight to age ratio. Thirty-two
(3.1%) patients were labeled as obesewith>120% expected weight
to age ratio and five (0.5%) patients were50% expected weight to
age.
Laboratory Characteristics
The median white blood cell (WBC) count available for 1,159
patients was 12.4 109/L, ranged 1 to 715 109/L. Only three
(0.3%) received steroid therapy prior to referral to the MECCA
member cancer center/hospital. The majority of patients 891
(76.9%) had low WBC with only 268 (23.1%) having WBC 50
 109/L. Of these patients, 174 (15%) patients presented with
hyperleukocytosis with WBC 100 109/L. A total of 1,162
patients had a mean hemoglobin 7.9 2.32 g/L and a median
platelet count of 36.6 109/L (range; 1–614) shown in Table I.
Morphologic (FAB) classification results showed the following:
730 (77.4%) had L1, 192 (20.4%) L2, and 21 (2.2%) L3 of a
reported total of 943. Immunophenotyping was available for 1,066
patient samples: 897 (84.2%) had B-lineage, 158 (14.8%) had T
cell, and 11 (1%) were classified as mature B cell (Fig. 2). Most of
the patients 1,009 (93.3%) did not have central nervous system
leukemia (CNS1), while 22 (2%) had CNS3 at diagnosis. An
additional 39 (3.6%) had CNS2 status, only 12 (1.1%) patients had
traumatic lumbar punctures (TLPs) and their CNS status was
decided according to the protocol used (Table I).
Genetic Characteristics
There were significant inter-and intra-country institutional
differences in the extent of genetic testing capabilities available.
Routine cytogenetic karyotyping was performed on only 496
(42.4%) patients, and this proportion varied greatly between the
member institutions. Some institutions were not able to perform
conventional cytogenetics. For others, the success rates range varied
from 12.5% to 100%. Patients were also tested by FISH and PCR
but as with karyotyping, the proportion of patients tested varied
significantly. The differences were seen among centers and among
the different translocations tested. However, large enough numbers
of patients were tested to evaluate the proportional representation of
Fig. 1. Number of patients (N¼ 1,171) and their age at diagnosis. A: Number of patients at each country; (B) distribution of age at diagnosis.
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TABLE I. Demographic, Clinical, Laboratory and Cytogenetic Profiles, Treatment Protocol, Risk Category, Nutritional Status and
Induction Outcomes
Characteristics N
Frequency (%),
meanSD
[median (range)] Characteristics N
Frequency (%),
mean SD
[median (range)]
Age at diagnosis (years) 1,171 6.08 3.90
[5.0 (0.2–18)]
Duration of symptoms (months) 1,135 1.35 1.64
[1.0 (0.1–15.0)]
Gender 1,171 Class of case and treatment sites 1,150
Male 692 (59.2) Received all treatment
in same hospital
1,114 (96.9)
Female 479 (40.8) Received treatment in different hospitals 36 (3.1)
Sign and symptoms Translocations (abnormalities)
Fever 870 (75.5) t(12;21)(p12;q22) 416 61 (14.7)
Bleeding 281 (25.0) t(1;19)(q23;p13) 259 16 (6.2)
Pallor 901 (79.2) t(4;11)(q21;q23) 462 24 (5.2)
Bruising/petechiae 342 (30.8) t(9;22)(q34;q11) 491 25 (5.1)
Bone pain 434 (39.6) t(9;11)(p21-22;q23) 99 1 (1.0)
Lymphadenopathy 712 (62.6) t(11;19)(q23;p13) 89 1 (1.1)
Splenomegaly 696 (60.8) t(7;9)(q34;q34.32) 77 1 (1.3)
Hepatomegaly 681 (59.5)
Testicular swelling 185 (26.7)
Other 178 (17.8)
CNS status 1,082 Pretreatment laboratory data
CNS1 1,009 (93.3) White blood cell (109/L) 1,159 54.0 103.8 [12.4 (1–715)]
CNS2 39 (3.6) WBC< 50 109/L 891 (76.9)
CNS3 22 (2.0) WBC 50 109/L 268 (23.1)
TLP 12 (1.1) Hemoglobulin (g/L) 1,162 7.9 2.3 [7.9 (2–15.7)]
Platelets (109/L) 1,162 66.1 81.1 [36.6 (1–614)]
Morphology 943 Risk category by reporting 1,101
L1 730 (77.4) Standard risk (SR) 519 (47.1)
L2 192 (20.4) Intermediate risk (IR) 186 (16.9)
L3 21 (2.2) High risk (HR) 396 (36.0)
Immunophenotype 1,066 B lineage risk category NCI/Rome 894
Precursor B 897 (84.2) Standard risk (SR) 622 (69.6)
T-cell 158 (14.8) High risk (HR) 272 (30.4)
Mature B 11 (0.9)
DNA index
(precursor B)
242
<1.16 135 (55.8) Testicular leukemic 17 (2.4)
1.16–1.60 101 (41.7)
>1.60 6 (2.5)
Cytogenetics
performed
Nutritional status 1,030
Yes 496 (42.4) Normal 120–80% weight/age 900 (87.4)
No 675 (57.6) Obese >120% expected weight/age 32 (3.1)
Grade I–IV <50–79% weight/age 98 (9.5)
Results of cytogenetics 433 Treatment protocol 1,171
Normal 284 (65.6) CCG 128 (10.9)
Abnormal 149 (34.4) BFM 351 (30.0)
SJCRH 111 (9.5)
UK 65 (5.5)
Modified international or local 516 (44.1)
End of Induction
outcomes
1,042 CBC at end of induction
M1 WBC (109/L) 1,051 4.9 3.1 [4.2 (0.2–36.4)]
M2 1,007 (96.6) Hemoglobin (g/L) 1,055 10.2 1.6 [10.1 (2–16.6)]
M3 21 (2.1) Platelets (109/L) 1,052 295.3 170.7 [271 (7–996)]
14 (1.3) ANC (%) 1,012 38.8 19.9 [40 (0–90)]
Blast (%) 996 0.4 4.1 [0 (0–80)]
CNS, central nervous system; TLP, traumatic lumbar puncture; ANC, absolute neutrophil counts; M1, complete remission; M2, incomplete
remission; M3, refractory disease; CCG, Children’s Cancer Group; BFM, Berlin-Frankfurt-Munster; SJCRH, St. Jude Children’s Research
Hospital; UK, United Kingdom; NCI, National Cancer Institute.
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these cytogenetic abnormalities. When calculating the proportion
positivity in the cohort, the denominator used varied by test and
depended on the ability of the particular test(s) to identify the
abnormality. Except ETV6–RUNX1 translocation, which is not
detectable by routine karyotyping, all translocation frequencies
were assessed using the three modalities of conventional
cytogenetics, FISH, and PCR.
ETV6–RUNX1 translocation was detected in 61 (14.7%) of
precursor B cell from the leukemia samples of 416 patients,
followed by TCF3–PBX1 in 16 (6.2%) of 259 tested. MLL gene
rearrangements were observed in 24 (5.2%) of 462 patients tested
and BCR–ABL1 demonstrated in 25 (5.1%) from 491 patients
tested. These and other translocations are shown in Table I.
Numerical chromosomal abnormalities were detectable by
karyotyping as well as by determination of the DNA index by flow
cytometry. Both of these methods were considered when
determining the cellular ploidy of leukemic blasts. DNA index
was not performed at many participating countries. It was done on
only 242 out of 897 (27%) of Precursor BALL samples: DNA index
of<1.16 in 135 (55.8%),1.16–1.6 in 101 (41.7%), and>1.60 in 6
(2.5%) (Table I). Cytogenetic data showed 119 (25.6%) had ALL
that was hyperdiploid out of a total number of 465 patients reported,
58 (15%) out of 387 patients reported having trisomies and 152
(30.6%) out of 496 patients reported having a diploid chromosome
number. Clear data were not available for other cytogenetic
abnormalities. Because testing for trisomies 4, 10, 17 was done in a
very small minority of patients, these results are not shown.
Treatment Protocol and Risk Categories
Multiple protocols were used as shown in Table I. Most of the
patients were treated on international protocols 655 (55.9%) and
516 (44.1%) on modified international or local protocols. By
Fig. 2. Institutional classification of ALL types.
Fig. 3. A: Risk category; (B) response to induction therapy.
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clinical criteria, 519 (47.1%) of the patients were assigned to the
low/standard-risk category, 186 (16.9%) to the intermediate, and
396 (36%) to the high-risk category. However, when we analyzed
risk category assignment using NCI/Rome criteria for precursor B
ALL, 622 (69.6%) were standard-risk and 272 (30.4%) were high-
risk group (Fig. 3A).
Response to Induction Therapy
Day 8 peripheral blood blasts count for 97 patients treated on
BFM protocol with available data showed 88 (90.7%) as good
steroid responders and 9 (9.3%) as poor steroid responders. Day 7
BM showed M1 in 66 (58.9%) and 23 (20.5%) as M2 or M3 bone
marrow, respectively, out of a total of 112 patients tested. By Day
15, of 619 patients reported, 552 (89.2%) hadM1 bone marrow, and
54 (8.7%) had M2 and 13 (2.1%) had M3 bone marrow. By the end
of induction, of 1,042 patients reported, 1,007 (96.6%) were in
complete remission. Twenty-one patients (2.1%) had M2 marrows
and 14 (1.3%) had disease refractory to therapy as defined by M3
marrow status (Table I and Fig. 3B). Various prognostic factors such
as age, gender, WBC, cell lineage, risk category by NCI/Rome,
CNS status, immunophenotype, DNA index, genotype, and
protocol showed no significant association with end of induction
response (P> 0.005; Table II).
Complications
Tumor lysis. Prior to treatment, 249 patients (26%) of 975 had
elevated uric acid level, 148 (18.0%) of 820 patients had elevated
phosphorus, and 27 patients (2.5%) of 1,069 elevated potassium. By
reporting, 10.1% of the patients had tumor lysis syndrome.
Bleeding. On presentation, 281 (25%) of the patients had
bleeding and, during induction 179 (15.3%) had bleeding and
received blood products.
Toxicities
Fever and neutropenia. Forty-eight percent of the 564
patients experienced fever and neutropenia during induction.
Eleven percent (11.4%) had documented infections, 91 (7.8%)
had bacterial sepsis, 35 (3%) had gram positive, 56 (4.8%) had
gram-negative sepsis, and 29 (2.5%) patients had shock with
infection and 10 (0.9%) patients had fungal infection.
Other Toxicities
Oral mucositis was observed in 249 (21.3%), diarrhea in 139
(11.9%), arrhythmias in 5 (0.4%), heart failure in 2 (0.2%), avascular
necrosis of the hip in 6 (0.5%), seizure in 10 (0.9%), motor neuropathy
in 9 (0.8%), and sensory neuropathy in 8 (0.7%) (Table III).
TABLE II. Association of Different Prognostic Variables With End of Induction Outcomes
N Complete remission Incomplete remission P-value
Age at diagnosis (years) 1,042
<1 20 (95.0) 1 (5.0) 0.752
1–10 798 (96.8) 26 (3.2)
10 189 (95.9) 8 (4.1)
Gender 1,042
Male 597 (96.8) 20 (3.2) 0.800
Female 410 (96.5) 15 (3.5)
White blood cell (109/L) 1,038
<50 773 (96.5) 28 (3.5) 0.685
50 230 (97.0) 7 (3.0)
Risk category by reporting 992
Standard risk (SR) 435 (97.3) 12 (2.7) 0.026
Intermediate risk (IR) 177 (98.9) 2 (1.1)
High risk (HR) 347 (94.8) 19 (15.2)
B lineage risk category by NCI/Rome 804
Standard risk (SR) 542 (97.7) 13 (2.3) 0.307
High risk (HR) 240 (96.4) 9 (3.6)
CNS status 985
CNS1 898 (96.8) 30 (3.2) 0.261
CNS2 34 (91.9) 3 (8.1)
CNS3 19 (95.0) 1 (5.0)
Immunophenotype 944
Precursor B 784 (97.3) 22 (2.7) 0.911
T-cell 134 (97.1) 4 (2.9)
Testicular leukemic 692
Yes 17 (100) 0 (0) 0.407
No 646 (96.1) 29 (3.9)
DNA index (precursor B) 235
<1.16 127 (97.7) 3 (2.3) 0.546
1.16–1.60 97 (98.0) 2 (2.0)
>1.60 6 (100) 0 (0)
CNS, central nervous system; NCI, National Cancer Institute.
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Co-morbidities: Fourteen patients had congenital chromosome
disorders most commonly trisomy 21 Down syndrome, 13 patients
had blood disorders, 2 patient immune deficiencies, 2 patients prior
malignancy, and 1 patient had prior myelodysplastic syndrome.
Mortality. Of the total 1,171, 1,042 (89%) had their end of
induction bone marrow reported. Of the remaining 129 (11%)
patients, who did not have their end of induction bone marrow
reported, 62 (48.1%) had missing data from one country (Syria).
There were less than 2% deaths in the entire cohort.
DISCUSSION
The clinical features and outcome results of childhood cancer in
the Middle East are largely unknown. This study is a first step
towards a better understanding of ALL, the most common
childhood malignancy, in the Middle East. We report the results
on 1,171 children. The study also represents the first large,
collaborative undertaking by institutions in the Middle East and
surrounding countries. However, this study does not include all
countries in the Middle East as some opted not to participate and
others could not submit the required data. Similarly, not all centers
in those countries who elected to participate were included in this
study. Efforts are needed to improve national and institutional
participation as well as accrual rates and quality of data submitted.
In spite of these limitations, this study demonstrates the willingness
and ability of investigators in the Middle East to create a functional
cooperative group.
The peak age range of 3–6 years is similar to the childhood ALL
reported from the west. Gender ratio of M/F (1.4:1) may be slightly
higher than reported gender ratio from the west. Among the signs
and symptoms, presentation with bone pain (39.6%) appears higher
than reported in the west and closer to Hong Kong report [12].
Although testicular involvement was suspected clinically in 185
(26.7%), only 17 (2.4%) had the confirmed diagnosis of testicular
leukemia. The high percentage of patients with suspected but not
confirmed testicular involvement reflects limited accuracy of
testicular involvement evaluation by clinical examination as
opposed to other diagnostic modalities such as biopsy. The majority
of patients 87.4% had normal nutritional status and only 3.1% were
obese. The overwhelming majority of patients (96.9%) received
care at their local or regional hospitals. Only 3% had to be
transferred to other hospitals. The duration of symptoms before
evaluation at the hospital was short with a median of 1 month and a
mean of 1.35 1.64 months; this appears comparable to delay time
reported from developed countries and much shorter than the
previous expectation which reflects improvement in public health
education, access to care and diagnostic facilities. It is also notable
that out of the total of 1,171 patients, only 12 patients (1.1%) had
TLP.
The French American British (FAB) classification of ALL
showed 77.4% L1, 20.4% L2, 2.2% L3 which is in keeping with
international data. T cell immunophenotype of 14.8% is also within
the percentage reported from the west, but possibly lower than
reported series in developing countries. This may reflect race and
ethnicity, geography, socio-economics status, environmental fac-
tors, and access to care [13–15].
There was no increase in the number of patients with higher risk
genetic lesions such as BCR–ABL1, MLL gene rearrangement and
TCF3–PBX. While the percentage of the hyperdiploidy (25.6%)
was similar to that reported in the west, the percentage of the other
favorable genetic marker ETV6–RUNX1 (14.7%) appeared lower
than reported in the west. Whether these lower incidence rate
related to variability in technical capacities of detecting these
genetic change will be subject of future MECCA studies.
The 14.7% of ETV6–RUNX1 appears lower than the 20%
incidence reported fromUnited States and Europe butmay be closer
to the rate reported from South Asia and some other developing
countries [16–22]. The lower proportion of “good risk” ALL has
been implicated as a contributing cause to the overall worse
outcome of patients. However, among Middle East countries and
other developing countries some have reported a 20% result similar
to USA and Europe [3]. Our 411 patients were tested by FISH and
PCR, but whether the lower representation is due to real difference
or technical issue will await next MECCA translational research
study. One future potential solution may be the establishment of a
MECCA referral laboratory which is capable of performing
advanced molecular studies. Such a laboratory would serve all
MECCA institutional members treating ALL. Data on cytogenetic
abnormalities were limited and were clearly reported on only 56%
of the patients who had cytogenetics tested. The distribution of
hyperdiploidy which is reported as 25.6% is similar to the 20–25%
TABLE III. Toxicities Reported During Remission Induction
Therapy
Toxicities N Percentage
Tumor lysis 118 10.1
Bleeding 179 15.3
Fever and neutropenia 564 48.2
Positive blood cultures 111 8.5
Bacteria 91 7.8
G positive 35 3.0
G Negative 56 4.8
Fungus 10 0.9
Urticaria 34 2.9
Anaphylaxis 4 0.3
Bronchospasm 14 1.2
Cardiac
Arrythmia 5 0.4
Heart failure 2 0.2
Gastrointestinal
Oral mucositis 249 21.3
Gastritis 111 9.5
Pancreatitis 8 0.7
Typhlitis 23 2.0
Diarrhea 139 11.9
Constipation 65 5.6
Musculoskeletal
Osteonecrosis 6 0.5
Osteoporosis 4 0.3
Neurotoxicity
Sensory neuropathy 8 0.7
Motor neuropathy 9 0.8
Paralysis 5 0.4
Seizure 10 0.9
Ataxia 3 0.3
Thrombotic events
Associated with central
venous catheter
2 0.2
Not associated with central
venous catheter
5 0.4
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reported from the west. Cytogenetic testing was done on 42.4% of
patients, which likely reflects the lack of well-established
cytogenetics laboratories in most of the Middle East countries.
Improvements are needed in the set up and standardize such testing
in the Middle East.
There are multiple different protocols used in the Middle East
and MECCA is trying to unify the diagnostic approach as well as
treatment protocols. By clinical and NCI/Rome criteria of risk
stratification, the percentage of high-risk patients which is about a
third of the patients is comparable to the percentage in the west.
Early steroid response, for patients treated on BFM protocol, as
assessed by Day 8 peripheral blood blast count (90.7% prednisone
good response) is compatible with reported literature from thewest.
End of induction remission rate (96.6%) and toxicities profile reflect
that the induction regimens used were effective and had tolerable
toxicities. Minimal residual disease (MRD) was not available
except at very few centers and thereforewas not reported. It is hoped
that in the future central MECCA lab will perform such tests. In
addition, a comparative analysis of ALL in the different countries as
well as the comparative analysis of B-lineage and T cell ALL will
be the subject of subsequent publications.
In conclusion, we believe that this study provides proof of
principle that collaborative clinical research with a centralized data
repository is feasible in the Middle East. The data derived from this
study have begun to demonstrate the clinical profile and disease
characteristics of ALL in the Middle East. We have identified areas
of needed improvement both in terms of diagnosis, risk classifica-
tion, and assessment of response. This effort is anticipated to lead to
standardization of diagnosis and adoption of a uniform protocol for
MECCA countries. MECCA efforts can lead to treatment strategies
and outcome, reduced morbidity and mortality and better quality of
life for children with cancer similar to the successful efforts of the
collaborative groups in North America and Europe.
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